Document:

aegr_EX_10_44

		
			Exhibit 10.44
		

		
			AMENDMENT NO.  1 TO EMPLOYMENT AGREEMENT 
		

		
			 
		

		
			This Amendment No. 1 to Employment Agreement (this “Amendment”), is entered into as of November 5, 2015, by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Gregory Perry (the “Employee”).
		

		
			WHEREAS, Employee and Company are parties to that certain Employment Agreement, dated as of June 26, 2015 (the “Employment Agreement); and
		

		
			WHEREAS, Employee and Company have agreed to amend certain provisions of the Employment Agreement;
		

		
			NOW, THEREFORE, in consideration of the mutual promises set forth herein, Company and Employee agree as follows: 
		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

					
						Retention Bonus Amount” shall mean any cash retention bonus awarded prior to the Date of Termination.

					
						 

					
						 

				
	
					
						 

					
					
						1.

					
					
						The following new definition shall be added to the Employment Agreement:

					
						 

					
						“Retention Bonus Amount” shall mean any cash retention bonus awarded prior to the Date of Termination.

					
						 

				
	
					
						 

					
					
						2.

					
					
						The final sentence of Section 7(b) of the Employment Agreement (entitled “Termination Due to Death or Disability”) shall be deleted in its entirety and replaced with the following:

					
						 

					
						“In the event of Employee’s termination as a result of Employee’s death or Disability, Employee or Employee’s estate or beneficiaries, as the case may be, shall be entitled only to the Accrued Obligations and the Retention Bonus Amount, and Employee shall have no further rights to any compensation or any other benefits under this Agreement.”

					
						 

				

		 

 

	
					
						 

					
					
						3.

					
					
						Section 7(d) of the Employment Agreement (entitled “Termination by the Company without Cause”) shall be deleted in its entirety and replaced with the following:

					
						 

					
						“(d)            Termination by the Company without Cause. The Company may terminate Employee’s employment at any time without Cause, effective upon Employee’s receipt of written notice of such termination. In the event that Employee’s employment is terminated by the Company without Cause (other than due to death or Disability) and provided that he fully executes and does not revoke an effective Release of Claims as described in Section 7(g), Employee shall be eligible for: 

					
						 

					
						(i)        The Accrued Obligations; 

					
						(ii)        The Severance Benefits;

					
						(iii)       At the end of the Severance Term, the Retention Bonus Amount; and

					
						(iv)       If such termination without Cause and the Date of Termination occur within eighteen (18) months after a Sale Event (as such term is defined in the Company’s 2010 Stock Option and Incentive Plan), acceleration of the vesting of 100% of Employee’s then outstanding unvested equity awards, such that all unvested equity awards vest and become fully exercisable or non-forfeitable as of the Date of Termination (the “Accelerated Equity Benefit”), in which case Employee shall have ninety (90) days from the Date of Termination to exercise the vested equity awards. 

					
						Notwithstanding the foregoing, the Severance Benefits shall immediately terminate, and the Company shall have no further obligations to Employee with respect thereto, in the event that Employee breaches any provision of the Confidentiality Agreement or the Release of Claims. Any such termination of payment or benefits shall have no effect on the Release of Claims or any of Employee’s post-employment obligations to the Company. Following such termination of Employee’s employment by the Company without Cause, except as set forth in this Section 7(d), Employee shall have no further rights to any compensation or any other benefits under this Agreement. For the avoidance of doubt, Employee’s sole and exclusive remedy upon a termination of employment by the Company without Cause shall be receipt of (i) the Severance Benefits (and, in the case of such a termination within eighteen (18) months after a Sale Event, the Accelerated Equity Benefit), subject to his execution of the Release of Claims, (ii) the Accrued Obligations, and (iii) at the end of the Severance Term, the Retention Bonus Amount, subject to his execution of the Release of Claims. 

					
						If the Company makes overpayments of Severance Benefits, Employee promptly shall return any such overpayments to the Company and/or hereby authorizes deductions from future Severance Benefit amounts.” 

				

		
			 
		

		
			 
		

		

		 

 

	
					
						 

					
					
						 

					
					
						 

					
						 

					
						 

					
						 

				
	
					
						 

					
					
						4.

					
					
						The final sentence of Section 7(e) of the Employment Agreement (entitled “Termination by Employee with Good Reason”) shall be deleted in its entirety and replaced with the following:

					
						 

					
						“For the avoidance of doubt, Employee’s sole and exclusive remedy upon a termination of employment with Good Reason shall be receipt of (i) the Severance Benefits (and, in the case of such a termination within eighteen (18) months after a Sale Event, the Accelerated Equity Benefit), subject to his execution of the Release of Claims, (ii) the Accrued Obligations, and (iii) at the end of the Severance Term, the Retention Bonus Amount, subject to his execution of the Release of Claims.”

					
						 

				
	
					
						 

					
					
						5.

					
					
						The first sentence of Section 7(g) of the Employment Agreement (entitled “Release”) shall be deleted in its entirety and replaced with the following:

					
						 

					
						“Notwithstanding any provision herein to the contrary, the payment of the Severance Benefits and the Retention Bonus Amount pursuant to subsection (d) or (e) of this Section 7 (other than the Accrued Obligations) shall be conditioned upon Employee’s execution, delivery to the Company, and non-revocation of the Release of Claims (and the expiration of any revocation period contained in such Release of Claims) in accordance with the time limits set forth therein.”

					
						 

				
	
					
						 

					
					
						6.

					
					
						Other Provisions. The Employment Agreement, as modified by this Amendment, shall remain in full force and effect. This Amendment may be executed in two or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument. The execution of this Amendment may be by actual or facsimile signature.

				

		
			[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 
		

		
			
		

		
			

		 

 

 
		

		
			IN WITNESS WHEREOF, the undersigned have executed this Amendment No. 1 to Employment Agreement as a sealed instrument as of the date first above written. 
		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

				
	
					
						AEGERION PHARMACEUTICALS, INC.

					
					
						 

					
					
						EMPLOYEE

				
	
					
						 

					
					
						 

				
	
					
						/s/ Mary Weger  ___________

					
						By:       Mary Weger

					
					
						 

					
					
						/s/ Gregory Perry_______________

					
						Gregory Perry

				
	
					
						Title:    Chief Performance Officer

					
					
						 

					
					
						Title:    Chief Financial Officer

				

		
			 
		

		
			
		

		
			

		 

 

AMENDEMENT NO. 3 TO EMPLOYMENT AGREEMENT 
		

		
			 
		

		
			This Amendment No. 3 to Employment Agreement (this “Amendment”), is entered into as of November 5, 2015, by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Mark Sumeray (the “Employee”).
		

		
			WHEREAS, Employee and Company are parties to that certain Employment Agreement, dated as of August 1, 2011, as amended as of September 1, 2011 and May 9, 2013 (the “Employment Agreement); and
		

		
			WHEREAS, Employee and Company have agreed to amend certain provisions of the Employment Agreement;
		

		
			NOW, THEREFORE, in consideration of the mutual promises set forth herein, Company and Employee agree as follows: 
		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

					
						Retention Bonus Amount” shall mean any cash retention bonus awarded prior to the Date of Termination.

					
						 

					
						 

				
	
					
						 

					
					
						1.

					
					
						The following new definition shall be added to the Employment Agreement:

					
						 

					
						“Retention Bonus Amount” shall mean any cash retention bonus awarded prior to the Date of Termination.

					
						 

				
	
					
						 

					
					
						2.

					
					
						The final sentence of Section 7(b) of the Employment Agreement (entitled “Termination Due to Death or Disability”) shall be deleted in its entirety and replaced with the following:

					
						 

					
						“In the event of Employee’s termination as a result of Employee’s death or Disability, Employee or Employee’s estate or beneficiaries, as the case may be, shall be entitled only to the Accrued Obligations and the Retention Bonus Amount, and Employee shall have no further rights to any compensation or any other benefits under this Agreement.”

					
						 

				

		 

 

	
					
						 

					
					
						3.

					
					
						Section 7(d) of the Employment Agreement (entitled “Termination by the Company without Cause”) shall be deleted in its entirety and replaced with the following:

					
						 

					
						“(d)            Termination by the Company without Cause. The Company may terminate Employee’s employment at any time without Cause, effective upon Employee’s receipt of written notice of such termination. In the event that Employee’s employment is terminated by the Company without Cause (other than due to death or Disability) and provided that he fully executes and does not revoke an effective Release of Claims as described in Section 7(g), Employee shall be eligible for: 

					
						 

					
						(i)        The Accrued Obligations; 

					
						(ii)        The Severance Benefits;

					
						(iii)       At the end of the Severance Term, the Retention Bonus Amount; and

					
						(iv)       If such termination without Cause and the Date of Termination occur within eighteen (18) months after a Sale Event (as such term is defined in the Company’s 2010 Stock Option and Incentive Plan), acceleration of the vesting of 100% of Employee’s then outstanding unvested equity awards, such that all unvested equity awards vest and become fully exercisable or non-forfeitable as of the Date of Termination (the “Accelerated Equity Benefit”), in which case Employee shall have ninety (90) days from the Date of Termination to exercise the vested equity awards. 

					
						Notwithstanding the foregoing, the Severance Benefits shall immediately terminate, and the Company shall have no further obligations to Employee with respect thereto, in the event that Employee breaches any provision of the Confidentiality Agreement or the Release of Claims. Any such termination of payment or benefits shall have no effect on the Release of Claims or any of Employee’s post-employment obligations to the Company. Following such termination of Employee’s employment by the Company without Cause, except as set forth in this Section 7(d), Employee shall have no further rights to any compensation or any other benefits under this Agreement. For the avoidance of doubt, Employee’s sole and exclusive remedy upon a termination of employment by the Company without Cause shall be receipt of (i) the Severance Benefits (and, in the case of such a termination within eighteen (18) months after a Sale Event, the Accelerated Equity Benefit), subject to his execution of the Release of Claims, (ii) the Accrued Obligations, and (iii) at the end of the Severance Term, the Retention Bonus Amount, subject to his execution of the Release of Claims.  

					
						If the Company makes overpayments of Severance Benefits, Employee promptly shall return any such overpayments to the Company and/or hereby authorizes deductions from future Severance Benefit amounts.” 

				

		
			 
		

		
			 
		

		

		 

 

	
					
						 

					
					
						 

					
					
						 

					
						at the end of the Severance Term, the Retention Bonus Amount, subject to his execution of the Release of Claims.”

					
						 

					
						 

				
	
					
						 

					
					
						4.

					
					
						The final sentence of Section 7(e) of the Employment Agreement (entitled “Termination by Employee with Good Reason”) shall be deleted in its entirety and replaced with the following:

					
						 

					
						“For the avoidance of doubt, Employee’s sole and exclusive remedy upon a termination of employment with Good Reason shall be receipt of (i) the Severance Benefits (and, in the case of such a termination within eighteen (18) months after a Sale Event, the Accelerated Equity Benefit), subject to his execution of the Release of Claims, (ii) the Accrued Obligations, and (iii) at the end of the Severance Term, the Retention Bonus Amount, subject to his execution of the Release of Claims.”

					
						 

				
	
					
						 

					
					
						5.

					
					
						The first sentence of Section 7(g) of the Employment Agreement (entitled “Release”) shall be deleted in its entirety and replaced with the following:

					
						 

					
						“Notwithstanding any provision herein to the contrary, the payment of the Severance Benefits and the Retention Bonus Amount pursuant to subsection (d) or (e) of this Section 7 (other than the Accrued Obligations) shall be conditioned upon Employee’s execution, delivery to the Company, and non-revocation of the Release of Claims (and the expiration of any revocation period contained in such Release of Claims) in accordance with the time limits set forth therein.”

					
						 

				
	
					
						 

					
					
						6.

					
					
						Other Provisions. The Employment Agreement, as modified by this Amendment, shall remain in full force and effect. This Amendment may be executed in two or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument. The execution of this Amendment may be by actual or facsimile signature.

				

		
			[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 
		

		
			
		

		
			

		 

 

 
		

		
			IN WITNESS WHEREOF, the undersigned have executed this Amendment No. 3 to Employment Agreement as a sealed instrument as of the date first above written. 
		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						AEGERION PHARMACEUTICALS, INC.

					
					
						 

					
					
						EMPLOYEE

				
	
					
						 

					
					
						 

				
	
					
						/s/ Mary Weger______________

					
						By:       Mary Weger

					
					
						 

					
					
						/s/ Mark Sumeray__________

					
						By:  Mark Sumeray

				
	
					
						Title:    Chief Performance Officer

					
					
						 

					
					
						Title:  Chief Medical Officer

				

		
			 
		

		
			
		

		
			

		 

 

AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT 
		

		
			 
		

		
			This Amendment No. 1 to Employment Agreement (this “Amendment”), is entered into as of November 5, 2015, by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Martha J. Carter (the “Employee”).
		

		
			WHEREAS, Employee and Company are parties to that certain Employment Agreement, dated as of February 14, 2011 (the “Employment Agreement); and
		

		
			WHEREAS, Employee and Company have agreed to amend certain provisions of the Employment Agreement;
		

		
			NOW, THEREFORE, in consideration of the mutual promises set forth herein, Company and Employee agree as follows: 
		

		
			 
		

			
					
						 

					
					
						1.

					
					
						The following new definition shall be added to the Employment Agreement:

					
						 

					
						“Retention Bonus Amount” shall mean any cash retention bonus awarded prior to the Date of Termination.

				
	
					
						 

					
					
						2.

					
					
						The third sentence of Section 7(b) of the Employment Agreement (entitled “Termination Due to Death or Disability”) shall be deleted in its entirety and replaced with the following:

					
						 

					
						“In the event of Employee’s termination as a result of Employee’s death or Disability, Employee or Employee’s estate or beneficiaries, as the case may be, shall be entitled only to the following:  (i) the Accrued Obligations; (ii) the Retention Bonus Amount, and (iii) if the Date of Termination occurs between January 1 and March 15 following the immediately preceding calendar year, then Employee shall be eligible to receive her earned Target Bonus, if any.”

				

		 

 

	
					
						 

					
					
						3.

					
					
						Section 7(d) of the Employment Agreement (entitled “Termination by the Company without Cause”) shall be deleted in its entirety and replaced with the following:

					
						 

					
						“(d)            Termination by the Company without Cause. The Company may terminate Employee’s employment at any time without Cause, effective upon Employee’s receipt of written notice of such termination. In the event that Employee’s employment is terminated by the Company without Cause (other than due to death or Disability) and provided that she fully executes and does not revoke an effective Release of Claims as described in Section 7(g), Employee shall be eligible for: 

					
						 

					
						(i)        The Accrued Obligations; 

					
						(ii)        The Severance Benefits;

					
						(iii)       If the Date of Termination occurs between January 1 and March 15 following the immediately preceding calendar year, then Employee shall be eligible to receive her earned Target Bonus, if any;

					
						(iv)      At the end of the Severance Term, the Retention Bonus Amount; and

					
						(v)       If such termination without Cause and the Date of Termination occur within eighteen (18) months after a Sale Event (as such term is defined in the Company’s 2010 Stock Option and Incentive Plan), acceleration of the vesting of 100% of Employee’s then outstanding unvested equity awards, such that all unvested equity awards vest and become fully exercisable or non-forfeitable as of the Date of Termination (the “Accelerated Equity Benefit”), in which case Employee shall have ninety (90) days from the Date of Termination to exercise the vested equity awards. 

					
						Notwithstanding the foregoing, the Severance Benefits shall immediately terminate, and the Company shall have no further obligations to Employee with respect thereto, in the event that Employee breaches any provision of the Confidentiality Agreement or the Release of Claims. Any such termination of payment or benefits shall have no effect on the Release of Claims or any of Employee’s post-employment obligations to the Company. Following such termination of Employee’s employment by the Company without Cause, except as set forth in this Section 7(d), Employee shall have no further rights to any compensation or any other benefits under this Agreement. For the avoidance of doubt, Employee’s sole and exclusive remedy upon a termination of employment by the Company without Cause shall be receipt of (i) the Severance Benefits (and, in the case of such a termination within eighteen (18) months after a Sale Event, the Accelerated Equity Benefit), subject to her execution of the Release of Claims, (ii) the Accrued Obligations, and (iii) at the end of the Severance Term, the Retention Bonus Amount, subject to her execution of the Release of Claims. 

					
						If the Company makes overpayments of Severance Benefits, Employee promptly shall return any such overpayments to the Company and/or hereby authorizes deductions from future Severance Benefit amounts.” 

				

		
			 
		

		

		 

 

	
					
						 

					
					
						4.

					
					
						The final sentence of Section 7(e) of the Employment Agreement (entitled “Termination by Employee with Good Reason”) shall be deleted in its entirety and replaced with the following:

					
						 

					
						“For the avoidance of doubt, Employee’s sole and exclusive remedy upon a termination of employment with Good Reason shall be receipt of (i) the Severance Benefits (and, in the case of such a termination within eighteen (18) months after a Sale Event, the Accelerated Equity Benefit), subject to her execution of the Release of Claims, (ii) the Accrued Obligations, and (iii) at the end of the Severance Term, the Retention Bonus Amount, subject to her execution of the Release of Claims.”

				
	
					
						 

					
					
						5.

					
					
						The first sentence of Section 7(g) of the Employment Agreement (entitled “Release”) shall be deleted in its entirety and replaced with the following:

					
						 

					
						“Notwithstanding any provision herein to the contrary, the payment of the Severance Benefits and the Retention Bonus Amount pursuant to subsection (d) or (e) of this Section 7 (other than the Accrued Obligations) shall be conditioned upon Employee’s execution, delivery to the Company, and non-revocation of the Release of Claims (and the expiration of any revocation period contained in such Release of Claims) in accordance with the time limits set forth therein.”

				
	
					
						 

					
					
						6.

					
					
						Other Provisions. The Employment Agreement, as modified by this Amendment, shall remain in full force and effect. This Amendment may be executed in two or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument. The execution of this Amendment may be by actual or facsimile signature.

				

		
			 
		

		
			[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 
		

		
			 
		

		
			 
		

		
			 
		

		
			IN WITNESS WHEREOF, the undersigned have executed this Amendment No. 1 to Employment Agreement as a sealed instrument as of the date first above written. 
		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

				
	
					
						AEGERION PHARMACEUTICALS, INC.

					
					
						 

					
					
						EMPLOYEE

				
	
					
						 

					
					
						 

				
	
					
						/s/ Mary Weger______________

					
						By:       Mary Weger

					
					
						 

					
					
						/s/ Martha J. Carter_______________

					
						By:       Martha J. Carter

				
	
					
						Title:    Chief Performance Officer

					
					
						 

					
					
						Title:    Chief Regulatory Officer

				

		
			 
		

		
			
		

		
			

		 

 

AMENDMENT NO. 1 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT 
		

		
			 
		

		
			This Amendment No. 1 to Amended and Restated Employment Agreement (this “Amendment”), is entered into as of November 5, 2015, by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Mary M. Weger (the “Employee”).
		

		
			WHEREAS, Employee and Company are parties to that certain Amended and Restated Employment Agreement, dated as of April 14, 2015 (the “Employment Agreement); and
		

		
			WHEREAS, Employee and Company have agreed to amend certain provisions of the Employment Agreement;
		

		
			NOW, THEREFORE, in consideration of the mutual promises set forth herein, Company and Employee agree as follows: 
		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

					
						Retention Bonus Amount” shall mean any cash retention bonus awarded prior to the Date of Termination.

					
						 

					
						 

				
	
					
						 

					
					
						1.

					
					
						The following new definition shall be added to the Employment Agreement:

					
						 

					
						“Retention Bonus Amount” shall mean any cash retention bonus awarded prior to the Date of Termination.

					
						 

				
	
					
						 

					
					
						2.

					
					
						The final sentence of Section 7(b) of the Employment Agreement (entitled “Termination Due to Death or Disability”) shall be deleted in its entirety and replaced with the following:

					
						 

					
						“In the event of Employee’s termination as a result of Employee’s death or Disability, Employee or Employee’s estate or beneficiaries, as the case may be, shall be entitled only to the Accrued Obligations and the Retention Bonus Amount, and Employee shall have no further rights to any compensation or any other benefits under this Agreement.”

					
						 

				

		 

 

	
					
						 

					
					
						3.

					
					
						Section 7(d) of the Employment Agreement (entitled “Termination by the Company without Cause”) shall be deleted in its entirety and replaced with the following:

					
						 

					
						“(d)            Termination by the Company without Cause. The Company may terminate Employee’s employment at any time without Cause, effective upon Employee’s receipt of written notice of such termination. In the event that Employee’s employment is terminated by the Company without Cause (other than due to death or Disability) and provided that she fully executes and does not revoke an effective Release of Claims as described in Section 7(g), Employee shall be eligible for: 

					
						 

					
						(i)        The Accrued Obligations; 

					
						(ii)        The Severance Benefits;

					
						(iii)       At the end of the Severance Term, the Retention Bonus Amount; and

					
						(iv)       If such termination without Cause and the Date of Termination occur within eighteen (18) months after a Sale Event (as such term is defined in the Company’s 2010 Stock Option and Incentive Plan), acceleration of the vesting of 100% of Employee’s then outstanding unvested equity awards, such that all unvested equity awards vest and become fully exercisable or non-forfeitable as of the Date of Termination (the “Accelerated Equity Benefit”), in which case Employee shall have ninety (90) days from the Date of Termination to exercise the vested equity awards. 

					
						Notwithstanding the foregoing, the Severance Benefits shall immediately terminate, and the Company shall have no further obligations to Employee with respect thereto, in the event that Employee breaches any provision of the Confidentiality Agreement or the Release of Claims. Any such termination of payment or benefits shall have no effect on the Release of Claims or any of Employee’s post-employment obligations to the Company. Following such termination of Employee’s employment by the Company without Cause, except as set forth in this Section 7(d), Employee shall have no further rights to any compensation or any other benefits under this Agreement. For the avoidance of doubt, Employee’s sole and exclusive remedy upon a termination of employment by the Company without Cause shall be receipt of (i) the Severance Benefits (and, in the case of such a termination within eighteen (18) months after a Sale Event, the Accelerated Equity Benefit), subject to her execution of the Release of Claims, (ii) the Accrued Obligations, and (iii) at the end of the Severance Term, the Retention Bonus Amount, subject to her execution of the Release of Claims. 

					
						If the Company makes overpayments of Severance Benefits, Employee promptly shall return any such overpayments to the Company and/or hereby authorizes deductions from future Severance Benefit amounts.” 

				

		
			 
		

		
			 
		

		

		 

 

	
					
						 

					
					
						 

					
					
						 

					
						her execution of the Release of Claims, (ii) the Accrued Obligations, and (iii) at the end of the Severance Term, the Retention Bonus Amount, subject to her execution of the Release of Claims.”

					
						 

					
						 

				
	
					
						 

					
					
						4.

					
					
						The final sentence of Section 7(e) of the Employment Agreement (entitled “Termination by Employee with Good Reason”) shall be deleted in its entirety and replaced with the following:

					
						 

					
						“For the avoidance of doubt, Employee’s sole and exclusive remedy upon a termination of employment with Good Reason shall be receipt of (i) the Severance Benefits (and, in the case of such a termination within eighteen (18) months after a Sale Event, the Accelerated Equity Benefit), subject to her execution of the Release of Claims, (ii) the Accrued Obligations, and (iii) at the end of the Severance Term, the Retention Bonus Amount, subject to her execution of the Release of Claims.”

					
						 

				
	
					
						 

					
					
						5.

					
					
						The first sentence of Section 7(g) of the Employment Agreement (entitled “Release”) shall be deleted in its entirety and replaced with the following:

					
						 

					
						“Notwithstanding any provision herein to the contrary, the payment of the Severance Benefits and the Retention Bonus Amount pursuant to subsection (d) or (e) of this Section 7 (other than the Accrued Obligations) shall be conditioned upon Employee’s execution, delivery to the Company, and non-revocation of the Release of Claims (and the expiration of any revocation period contained in such Release of Claims) in accordance with the time limits set forth therein.”

					
						 

				
	
					
						 

					
					
						6.

					
					
						Other Provisions. The Employment Agreement, as modified by this Amendment, shall remain in full force and effect. This Amendment may be executed in two or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument. The execution of this Amendment may be by actual or facsimile signature.

				

		
			[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 
		

		
			
		

		
			

		 

 

 
		

		
			IN WITNESS WHEREOF, the undersigned have executed this Amendment No. 1 to Employment Agreement as a sealed instrument as of the date first above written. 
		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

				
	
					
						AEGERION PHARMACEUTICALS, INC.

					
					
						 

					
					
						EMPLOYEE

				
	
					
						 

					
					
						 

				
	
					
						__/s/ Gregory Perry______________

					
						By:       Gregory Perry

					
					
						 

					
					
						_/s/ Mary Weger          ______

					
						By:  Mary Weger

				
	
					
						Title:    Chief Financial Officer

					
					
						 

					
					
						Title:    Chief Performance Officeraegr_EX_10_45

		
			
		

		
			Exhibit 10.45
		

		
			Mark Sumeray
		

		
			Temporary Assignment Plan
		

		
			In order to provide strategic support to the European business during a critical time of reimbursement, pricing, and launch of Lojuxta in addition to Myalept registration and prelaunch planning, Aegerion has agreed to a temporary assignment, not to exceed one year, for Dr. Mark Sumeray in Germany. Dr. Sumeray will maintain his position of Chief Medical Officer responsible for Aegerion’s Global Clinical development, Research, PV and Medical Affairs strategy and Operations and thereby ensure a presence in Cambridge for Managerial meetings, employee 1:1’s, coaching and development and appropriate “networking maintenance” during this temporary assignment plan.  Dr. Mark will make a special effort to enable access for his direct report group during the period he is working from Germany.  This may require evening conference calls from Europe given the six (6) hour time change. This plan is contingent upon continuing high performance. Below are specific objectives Mark will achieve to assist the EMEA as part of this assignment. The Temporary Assignment Plan terms are as follows:
		

		
			Effective: October 1, 2015 – September 30, 2016 
		

		
			TERMS
		

			
	
			
				 ·
			

			
	
			
			Incidental Assignment Allowance:  ($33,750) Grossed up.  

			
	
			
				 ·
			

			
	
			
			Temporary Lodging Expenses:  As part of this temporary assignment, we will reimburse Dr. Sumeray the cost of actual lodging expenses (in the form of rent and utilities) not to exceed the lesser of a) $4750 per month ($57,000 annualized) during the term of this temporary assignment) or b) the per diem lodging rates allowable for Munich, Germany as established by the US Department under Federal Travel Regulations. Reimbursements will be supported by documented expenses. 

			
	
			
				 ·
			

			
	
			
			As a temporary assignment, all travel –except travel related to Holidays/vacation- will be treated as business expenses. This includes hotels, airfare, and taxis.

			
	
			
				 ·
			

			
	
			
			We will provide tax assistance not to exceed $5k for term of this temporary assignment as needed.

		
			   EMEA GOALS
		

			
	
			
				 ·
			

			
	
			
			European Myalept filing for generalized lipodystrophy and strategy for severe PL indication

			
	
			
				 ·
			

			
	
			
			CAPTURE study – implementation in Europe 

			
	
			
				 ·
			

			
	
			
			Germany GBA – strategy and implementation of GBA process for market access in Germany

			
	
			
				 ·
			

			
	
			
			France CEPS – value arguments to support pricing

			
	
			
				 ·
			

			
	
			
			Early access program in EU (Myalept NPS – French ATU, Italian law 648)

			
	
			
				 ·
			

			
	
			
			Work in close coordination and communication with David Allmond, our new President – EMEA

			
	
			
				 ·
			

			
	
			
			Assist in all possible ways to gain reimbursement in key European countries through a coordinated effort of creating KOL support and patient advocacy

		
			Agreed:
		

		
			/s/ Mark Sumeray____
		

		
			Mark Sumeray

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}]]